LICART Drug Patent Profile
✉ Email this page to a colleague
When do Licart patents expire, and when can generic versions of Licart launch?
Licart is a drug marketed by Ibsa Inst Bio and is included in one NDA.
The generic ingredient in LICART is diclofenac epolamine. There are forty-seven drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the diclofenac epolamine profile page.
Summary for LICART
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 1 |
| Formulation / Manufacturing: | see details |
| What excipients (inactive ingredients) are in LICART? | LICART excipients list |
| DailyMed Link: | LICART at DailyMed |
Recent Clinical Trials for LICART
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| IBSA Institut Biochimique SA | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for LICART
US Patents and Regulatory Information for LICART
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ibsa Inst Bio | LICART | diclofenac epolamine | SYSTEM;TOPICAL | 206976-001 | Dec 19, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
